LEXINGTON, Mass., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop next generation targeted drug candidates for the treatment of human cancers, today announced the appointment of Jaye Viner, M.D. as Chief Medical Officer and Executive Vice President. Dr. Viner will be responsible for the leadership of Curis' clinical development strategy and efforts to further the development of its pipeline of proprietary drug candidates. In addition to Dr. Viner's appointment, Curis also announced the appointment of Tania Chander, Pharm.D. as Vice President of Product Development. Dr. Chander will be responsible for project leadership throughout the product development process. "We are delighted to have Drs. Viner and Chander join the Curis team as we seek to implement the next stage of our corporate development strategy. These strategic appointments further Curis' mission to strengthen its clinical oncology capabilities," said Ali Fattaey, Curis' President and Chief Operating Officer. "We are highly encouraged by the prospects of our proprietary clinical-stage drug candidates and Jaye and Tania's joining coincides with Curis' strategic transition and focus on innovative and effective clinical development. We believe that Jaye's molecular oncology knowledge, combined with broad experience across clinical oncology development, will tremendously enhance our internal capabilities as we seek to effectively and efficiently develop our clinical programs, including CUDC-427, our IAP antagonist, and CUDC-907, our dual-acting PI3K and HDAC inhibitor. Moreover, Tania's expertise in product leadership will help shape our strategy as we drive our development programs into multiple near-term clinical trial launches." "I am excited to lead Curis' clinical efforts to advance science- and data-driven development of novel therapeutics. I look forward to working with this dedicated team to explore the therapeutic potential of promising agents for patients with cancer," said Dr. Viner. Dr. Viner will replace Maurizio Voi, M.D. who has departed Curis to pursue other opportunities. The Curis team thanks Maurizio for his contributions and wishes him success in his future endeavors.